Kabergolin Testmiljö
Kabergolin
Klass : A
Visa all info
Skriv ut
Kontakta oss
Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.
Dostinex (cabergoline). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2015-10-14, cited 2019-11-25]
Cabaser (cabergoline). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2016-10-20, cited 2019-11-25].
Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633-45.
Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148:325-31.
Khare S, Lila AR, Patt H, Yerawar C, Goroshi M, Bandgar T et al. Gender differences in macroprolactinomas: a single centre experience. Endocr Connect. 2016;5(1):20-7.
Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518-22.
Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010;72:53-8.
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
- Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.
- Dostinex (cabergoline). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2015-10-14, cited 2019-11-25]
- Cabaser (cabergoline). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2016-10-20, cited 2019-11-25].
- Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633-45.
- Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148:325-31.
- Khare S, Lila AR, Patt H, Yerawar C, Goroshi M, Bandgar T et al. Gender differences in macroprolactinomas: a single centre experience. Endocr Connect. 2016;5(1):20-7.
- Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518-22.
- Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010;72:53-8.
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]